The drug, Aduhelm, had received mixed reviews following earlier clinical trials
By Alexandria Hein
The Food and Drug Administration (FDA) on Monday approved Biogen’s Alzheimer’s drug, marking the first new authorized therapy to treat the disease in nearly two decades. The drug, Aduhelm (aducanumab), had received mixed reviews following earlier clinical trials.
In a statement following the approval, Dr. Patrizia Cavazzoni, director of the FDA Center for Drug Evaluation and Research, said the agency used the Accelerated Approval pathway, which is when the FDA “approves a drug for a serious or life-threatening illness that may provide…
Click the link below to read the rest of this story.
Click here to get more news from the Bulldog
On the go, but don’t want to miss any Bulldog news? Go to the App Store and downloads apps for Bulldog Reports and The Bulldog Show to your Apple and Android mobile devices. It’s free!